



222 Third Street
Cambridge, MA 02142
Voice (617) 576-9400
Fax (617) 576-9430
www.Fibroids1.com
support@Fibroids1.com

Press Release

Contact: Kelly Schrade (kschrade@body1.com)

BOSTON SCIENTIFIC AND BODY1 LAUNCH ONLINE RESOURCE FOR WOMEN SUFFERING FROM UTERINE FIBROIDS

- FIBROIDS1.COM DEBUTS AS A COMPREHENSIVE RESOURCE FOR THE MILLIONS OF WOMEN SUFFERING FROM UTERINE FIBROIDS -

CAMBRIDGE, MA, Dec 4, 2003 -- Boston Scientific Corporation (NYSE: "BSX") and Body1, Inc. today announced the launch of www.fibroids1.com. Fibroids1.com is a knowledge community, or "KnowCo", site for women suffering from uterine fibroids. In the US alone there are approximately 6 million women who suffer from uterine fibroids, non-cancerous tumors that can cause excessive bleeding and pain. The launch of Fibroids1.com provides these women and their families with a comprehensive resource for valuable information on uterine fibroids and potential treatment options.

This alliance creates an Internet-based channel, supported by Boston Scientific, to provide educational information about new medical technologies for treating uterine fibroids. Fibroids1.com highlights Boston Scientific's recent advances with Uterine Fibroid Embolization (UFE), a minimally invasive, uterus-sparing procedure. In UFE, tiny embolic particles are injected into the blood vessels feeding the fibroids. Recent medical studies have shown that UFE offers women a minimally invasive procedure that can provide effective symptom relief and shorter recovery times when compared to surgical options. Boston Scientific has developed Contour®, a leading embolic particle made of Polyvinyl Alcohol (PVA).

"With Fibroids1.com we now are supporting a powerful, comprehensive educational resource to help the millions of women who suffer from fibroids," said Dave McClellan, President of the Oncology business at Boston Scientific. "In addition, the Fibroids1.com Physician Locator lists contact information for participating physicians who use Boston Scientific embolic products and may provide an excellent resource for women searching for a physician close to home."

"We are delighted to work with such an important leader in medical technologies for patient care as Boston Scientific," said Chris Messina, CEO of Body1, Inc. "They have a terrific team for advancing medical innovations, including those in consumer healthcare education. In addition, Boston Scientific has proven that they have all the ingredients for advancing the state of the art in patient care- the vision, the people, and the products."

About Body1, Inc.

Body1, Inc. educates targeted populations on behalf of medical product manufacturers through its network of knowledge communities, or "KnowCo's" such as <http://www.Heart1.com>, <http://www.Reflux1.com>, and <http://www.Knee1.com>. In addition to patient education, Body1 provides interactive, knowledge-based tools for online medical education programs (the eForums suite). It also provides accredited physicians with complementary websites through <http://www.Doctors1.org>. Body1's programs all accelerate the adoption of novel approaches that enhance human health.

The Body1 Network is one of the most visited online health networks with over 3 million visits per year and is accredited by the Health on the Net (HON) Foundation.

CONTACT: Kelly Schrade (kschrade@body1.com) 617-576-9400

**About Boston Scientific**

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.

CONTACT: Charles Rudnick (508-650-8660), Media Relations

For Immediate Release December 4, 2003 12pm EST